paxilline has been researched along with Esophageal Squamous Cell Carcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Fan, T; Gao, P; Hui, Y; Liu, H; Xu, P; Zhang, L; Zhang, X | 1 |
1 other study(ies) available for paxilline and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway.
Topics: Animals; Apoptosis; Carboxylic Ester Hydrolases; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Focal Adhesion Protein-Tyrosine Kinases; Gene Knockdown Techniques; Humans; Matrix Metalloproteinase 2; Mice, Nude; Mitochondrial Proteins; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Paxillin; Protein Binding; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |